Navigation Links
NeoStem Provides Update on Amorcyte Clinical Progress and Reports Results for Second Quarter
Date:8/15/2011

ially greater statistical power. A composite of cardiac measures, including clinically meaningful endpoints, will support the primary endpoint of perfusion. "Though the plan was to enroll the first patient early in 2012, we are now confident that we will begin the Phase II program ahead of schedule," said Dr. Pecora.

Dr. Robin Smith, NeoStem CEO, said, "We are thrilled to see Amorcyte advancing through the FDA's drug development process and moving forward with the Phase II clinical trial. We believe that AMR-001 represents a potential breakthrough therapy for a large unmet medical need. We see tremendous potential pharmacoeconomic benefit in this therapy, which we believe could change both the clinical adverse events associated with serious heart attacks and improve a patient's quality of life, all with one therapeutic intervention." 

NeoStem continues its transition to cell based therapeutics and Progenitor Cell Therapy ("PCT's") capabilities in quality cell manufacturing are a key advantage in the development of AMR-001 as well as future cell-based therapeutics candidates the Company may pursue.

NeoStem reported its unaudited results for the three and six months ended June 30, 2011. Revenues for the three and six months ended June 30, 2011 were $18.5 million and $38.1 million compared to $19.4 million and $35.2 million for the same periods in 2010.  Revenues in its Pharmaceutical Manufacturing – China business for the three and six months ended June 30, 2011 reflected lower sales due to a strategic decision by management to discontinue selling certain pharmaceutical intermediates to other pharmaceutical manufacturers, in order to create capacity within the existing production lines for higher margin products in the future.

Net losses attributable to NeoStem's controlling interests for the three and six months ended June 30, 2011 were $10.8 million or $0.13 per share (including $4.6 million of non-cash equity-based compe
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit
2. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
3. NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceutical Company
4. NeoStem, Inc. Names Edward Geehr, M.D. to Board of Directors; Biotechnology Executive Brings Scientific and Business Experience in Global Operations
5. NeoStem Announces Warrant Exercise by Principal Shareholder
6. NeoStem, Inc. Officially Launches Adult Stem Cell Collection Center and R&D Laboratory in Cambridge, Massachusetts
7. NeoStem Pharmaceutical Subsidiary Announces Two cGMP Lines are Now Fully Operational in New Facility
8. NeoStem Adds Distinguished Researcher to its World-Class Scientific Advisory Board
9. NeoStem Comments on Recent Court Ruling Blocking the Federal Governments Funding of Embryonic Stem Cell Research
10. NeoStem and Progenitor Cell Therapy Announce Entry Into Merger Agreement
11. NeoStem to Present at Cell Therapy Industry Summit to be held on November 3-5, 2010 in Carlsbad, California
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... The Parenteral Drug Association (PDA) is moving ... protocols. The new initiative stems from ... industry participants and regulatory authority representatives at the PDA ... Washington, DC . Representatives of both the ... workshop. Attendees indicated openness to engaging regulators and industry ...
(Date:9/19/2014)... Calif. , Sept. 19, 2014 Today, iHealth ... capital from Xiaomi Ventures, Ltd. for its first institutional ... to continue expanding iHealth,s global reach, accelerate growth and ...  As part of the investment, Xiaomi Ventures will join ... areas of cloud infrastructure and ecommerce. "We ...
(Date:9/19/2014)... DUBLIN , September 19, 2014 /PRNewswire/ ... http://www.researchandmarkets.com/research/s6g5wm/global ) has announced the addition of ... report to their offering. ... devices have been broadly classified into wide ... are used for the treatment of different ...
Breaking Medicine Technology:PDA Launches Effort to Harmonize Global Post-Approval Changes Protocols 2iHealth Raises $25 Million to Fuel Growth and Global Market Share 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3
(Date:9/19/2014)... “Copay coupons,” a drug manufacturer marketing tactic ... patients with prescription drug coverage, may now be infiltrating ... from the Department of Health and Human Services ... prohibit suppliers from offering side-payments to increase sales of ... The report highlights that two recent surveys, including one ...
(Date:9/19/2014)... New York, NY (PRWEB) September 19, 2014 ... by PR News at the Platinum PR and Top ... Grand Hyatt in New York City. Camino received honorable ... a Shoestring Campaign” — for its work elevating Latina ... with this incredible organization and be a part of ...
(Date:9/19/2014)... NY (PRWEB) September 19, 2014 According ... manufacturers of the embattled blood-thinner Xarelto, named as defendants ... of Common Pleas, have moved the court to dismiss ... do not have sufficient connection with Philadelphia.* The cases ... et al. (No. 140304328; Pa. Comm. Pls., Philadelphia Cty.), ...
(Date:9/19/2014)... -- Although there is mounting evidence that muscle-strength ... older adults in the United States don,t engage ... research. Less than one-quarter of adults over ... Department of Health and Human Services, the study ... health and fitness and staying independent, researchers advised. ...
(Date:9/19/2014)... MetroMD, a leading anti-ageing clinic has called its HGH ... therapy has grown tremendously across USA in the last decade ... dependable. It has far reaching benefits for ageing men and ... healthy and active lifestyle even beyond their middle age. ... at MetroMD said, “HGH or Human Growth hormones are the ...
Breaking Medicine News(10 mins):Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2
... , , MONDAY, May 19 (HealthDay News) -- Findings from two ... erectile dysfunction can be a powerful early warning sign for ... men with diabetes but no signs of heart disease found ... percent more likely to have a heart attack or other ...
... of Nebraska Medical Center-led pilot study that showed antidepressants ... and neck cancer patients is the focus of an ... one of the publications produced by the Journal of ... led by UNMCs William Lydiatt, M.D., and Bill Burke, ...
... study from University Hospitals Case Medical Center (UHCMC) finds ... with malignant brain tumors are not treated as aggressively ... Furthermore, the researchers find that if patients over 75 ... and radiation, they have better survival rates. The findings ...
... have new life as a stroke treatment, researchers say. ... ways inhibiting white blood cells and enzymes that, ... vessels, respectively, says Dr. David Hess, chair of the ... School of Medicine. The broad-spectrum antibiotic also seems to ...
... May 19 Baker Energy, a unit,of Michael ... that the Wyoming,State Department of Environmental Quality (DEQ) ... (Huber), with a first-of-its-kind award,for their joint commitment ... http://www.newscom.com/cgi-bin/prnh/20061214/BAKERLOGO ), Wyoming DEQ Storm ...
... a nationwide clinical trial led by a University of ... ablation is an effective treatment for dysplasia in people ... deadly gastrointestinal cancer. , The interim results show there ... and a placebo or sham treatment, said Dr. Nicholas ...
Cached Medicine News:Health News:Erectile Dysfunction a Strong Harbinger of Heart Trouble 2Health News:Erectile Dysfunction a Strong Harbinger of Heart Trouble 3Health News:JAMA publication features study on depression and head and neck cancer 2Health News:Study: Patients 75 years and older with brain tumors may benefit from more aggressive treatment 2Health News:Old antibiotic may find new life as a stroke treatment 2Health News:Old antibiotic may find new life as a stroke treatment 3Health News:Baker Energy and Huber Receive First-of-its-Kind Award from Wyoming Department of Environmental Quality 2Health News:Baker Energy and Huber Receive First-of-its-Kind Award from Wyoming Department of Environmental Quality 3Health News:Radiofrequency ablation is effective treatment for dysplasia in Barrett's esophagus 2
BD Vacutainer® Heparin Tubes are spray-coated with either lithium heparin or sodium heparin and are used for plasma determinations in chemistry....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
... Coagulation tubes contain a buffered ... available with a citrate concentration ... 0.129 mol/l (3.8%). The mixing ... solution to 9 parts blood. ...
... are available in two versions. ... a clotting activator and is ... serum is required for testing ... is suitable where the testing ...
Medicine Products: